GlaukosGKOS -1.52%80 Debt-to-Equity is 0.15 as of Mar. 2026, which is 63% below its 10-year median of 0.41. GuruFocus rates GKOS with a GF Score™ of 80/100 and a GF Value™ of $136.41 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 704 Medical Devices & Instruments companies, Glaukos ranks better than 60.09% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Glaukos's Debt-to-Equity or its related term are showing as below:
GKOS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.41 Max: 0.85
Current: 0.15
During the past 13 years, the highest Debt-to-Equity Ratio of Glaukos was 0.85. The lowest was 0.03. And the median was 0.41.
GKOS's Debt-to-Equity is ranked better than 60.09% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs GKOS: 0.15
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Glaukos Debt-to-Equity Related Terms
Glaukos Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Glaukos's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKOS vs BIO, BRKR, PODD: Debt-to-Equity Comparison
For the Medical Devices subindustry, Glaukos's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glaukos Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Glaukos's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos (GKOS) has a Debt-to-Equity of 0.15 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Glaukos and its competitors. This is 63% below median its historical median of 0.41. Over the past decade, Glaukos' Debt-to-Equity has ranged from 0.03 to 0.85. According to the industry distribution chart, Glaukos ranks #281 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 39.9%.
Is Glaukos' Debt-to-Equity too high?
Glaukos' current Debt-to-Equity of 0.15 is 63% below median its 10-year median of 0.41. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.85. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Glaukos' value of 0.15 is 33.3% below this industry median. Based on the distribution chart, Glaukos ranks #281 out of 704 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Glaukos has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Debt-to-Equity compare to BIO and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Glaukos ranks #281 out of 704 companies for Debt-to-Equity. This puts Glaukos in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Glaukos' value of 0.15 is 33.3% below this benchmark. Historically, Glaukos' own Debt-to-Equity has ranged from 0.03 to 0.85 over the past decade. While the company's 10-year median is 0.41 vs. the industry median of 0.23, Glaukos has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glaukos's current Debt-to-Equity of 0.15 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Glaukos and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glaukos's current Debt-to-Equity is 0.15, which is 63% below median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Modestly Overvalued. The stock's GF Value™ is $136.41, compared to a current price of $152.72 — trading 12% above its estimated fair value. The current Debt-to-Equity is 0.15, which is 63% below median its 10-year median of 0.41 and 33.3% below the Medical Devices & Instruments industry median of 0.23. Glaukos' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Glaukos (GKOS), the current Debt-to-Equity is 0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glaukos (GKOS) Overvalued in 2026?
Based on GuruFocus' analysis, Glaukos stock appears to be overvalued.
The current stock price of $152.72 is trading 12% above its estimated GF Value™ of $136.41.
GuruFocus considers Glaukos to be Modestly Overvalued.
Key valuation signals for GKOS:
Debt-to-Equity: 0.15 (63% below median its 10-year median of 0.41)
GF Value™: $136.41 vs. price of $152.72 (12% above fair value)
Industry Position: 33.3% below the Medical Devices & Instruments median (#281 of 704)
No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
80GF Score
Get the complete analysis for GKOS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GKOS has been successfully added to your 
